351. [Empirical treatment of febrile episodes in patients with neutropenia in bone marrow transplantation].
- Author
-
Pérez M, Muruzábal MJ, Gómez Casares MT, Alsar MJ, Conde E, Iriondo A, Garijo J, Richard C, Baro J, and Aguado JM
- Subjects
- Adult, Aminoglycosides, Drug Resistance, Microbial, Drug Therapy, Combination therapeutic use, Female, Fever etiology, Fever microbiology, Gram-Negative Bacteria drug effects, Humans, Male, Premedication adverse effects, Retrospective Studies, Sepsis etiology, Anti-Bacterial Agents therapeutic use, Bone Marrow Transplantation, Cephalosporins therapeutic use, Fever drug therapy, Neutropenia complications, Sepsis drug therapy, Ticarcillin therapeutic use, Trimethoprim, Sulfamethoxazole Drug Combination therapeutic use
- Abstract
The results of therapy of febrile episodes during the pregraft phase in bone marrow transplant was retrospectively evaluated in 84 granulocytopenic patients. Most patients received co-trimoxazole and i.v. ticarcillin as antibacterial prophylaxis. 47 episodes were treated with a third generation cephalosporin plus an aminoglycoside, with a 55% favorable response rate. 37 episodes were treated with a wide spectrum penicillin plus an aminoglycoside, with a 41% response rate (p greater than 0.05). Among the 23 infections caused by gram-negative bacilli the response rate was 89% (8 of 9) with the first regimen, and 21% (3 of 14) with the second one (p = 0.003). The investigation of in vitro sensitivity suggested that prophylactic ticarcillin favors the infections due to bacilli with cross-resistance to wide spectrum penicillins. The antibiotic regimen did not influence the final resolution or the mortality rate of the febrile episode.
- Published
- 1990